Project Grant HT94252510531

This Project Grant award for $597,683 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop an injectable piezoelectric nanocomposite hydrogel scaffold to promote healing of major load-bearing cartilage defects in large animal models. The proposed research seeks to advance a novel injectable scaffold made of piezoelectric poly-L-lactide...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has awarded Collamedix Inc. a $300,000 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to establish the feasibility of their "CollaLink" collagen-based scaffold for augmenting primary repair of anterior cruciate ligament (ACL) mid-substance tears. The project aims to demonstrate that the CollaLink scaffold, when placed around an ACL tear, can provide a...

This $367,577 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Adepthera LLC aims to develop a regenerative peptide therapy to accelerate pressure ulcer healing. Specifically, the award will fund research to identify an optimal formulation of a self-assembling adrenomedullin (ADM) analog gel that can improve local blood circulation and wound healing in aging and diabetic mouse models. The proposed therapy would be administered weekly or biweekly via...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research aims to identify FDA-approved drugs that can stimulate lubricin production in human chondrocytes as a potential disease-modifying approach for post-traumatic osteoarthritis (PTOA). The $413,688 award to the University of Central Florida will support the development of a lubricin reporter cell system to screen...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Panorama Research Incorporated, doing business as Panorama Research Inc., a $275,765 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop an antibody-based therapy for reducing scarring and fibrosis following joint surgeries. The project aims to improve the delivery and tissue residence of a lead humanized antibody that inhibits collagen fibril formation, thereby...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $549,437 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, effective September 1, 2024 through June 30, 2029, aims to develop a novel therapy that leverages the Hedgehog signaling pathway to improve tendon-to-bone...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to identify peptides that preferentially localize to osteoarthritic (OA) joints after intravenous injection and leverage these peptides to develop targeted OA drug carriers. The $208,627 award, granted on Jul 11, 2024, will fund research activities at the University of Florida and the...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...

This $312,871 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports the development of a novel pro-angiogenic bone coating hydrogel (ABC Hydrogel) for the treatment of osteonecrosis. The key products and services to be delivered through this 5-year grant include: 1) characterizing the physical, chemical, and cytocompatibility properties of the ABC...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $501,450 to The Washington University to conduct research on regulating tendon repair using stem cell-derived extracellular vesicles. The study aims to identify the specific subpopulation and active cargo molecules of extracellular vesicles that can enhance tendon healing and avoid...